Morgan Stanley raised the firm’s price target on Alnylam to $255 from $250 and keeps an Equal Weight rating on the shares. The firm is largely in-line with consensus and expects Q2 TTR franchise revenues to be approximately flat quarter-over-quarter, the analyst tells investors in a small-to-mid cap Biotechnology group preview.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ALNY: